טוען...
Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
BACKGROUND: The effect of the addition of fotemustine and/or interferon (IFN) to standard therapy with dacarbazine alone in patients with advanced malignant melanoma was investigated in a multicenter, randomized 2x2 factorial design trial. METHODS: A total of 260 patients were randomly assigned to o...
שמור ב:
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
פורמט: | Artigo |
שפה: | Inglês |
יצא לאור: |
BioMed Central
2013
|
נושאים: | |
גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3598549/ https://ncbi.nlm.nih.gov/pubmed/23402397 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-11-38 |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|